Bioventus Inc. (BVS)
Bioventus Inc. (BVS) from its SEC filings: 2025 revenue $568.1 million (-1% vs the year before), net margin 4%, free cash flow $72.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $568.1 million |
| Revenue growth | -1% |
| Net income | $22.7 million |
| Net margin | 4.0% |
| Free cash flow | $72.1 million |
| Diluted EPS | $0.33 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +4% |
| Cash | $29.5 million |
| Long-term debt | $229.7 million |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.